Avid Bioservices Inc (CDMO)

[jakedogman1]

another good article...

http://www.fiercebiotech.com/biotech/armo-taps-celgene-gv-for-67m-to-fuel-late-phase-i-o-r-d

and pphm has lag3 preclinical data...

Suggestions of synergies between LAG-3 and PD-1 have led a who’s who of immuno-oncology players to move assets into human testing. Bristol-Myers, Novartis, Regeneron and Tesaro already have LAG-3 drugs in the clinic. Yet, as with its PD-1 program, Armo and its investors see value in moving a LAG-3 candidate forward for use in an anticipated slate of combination therapies.